Inhibikase Therapeutics, Inc. (IKT) vs Lexeo Therapeutics, Inc. Common Stock (LXEO)
A side-by-side comparison of Inhibikase Therapeutics, Inc. and Lexeo Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IKT
Inhibikase Therapeutics, Inc.
$1.98HealthcareDelayed quote: Oct 6, 2026, 10:24 AM EDT
LXEO
Lexeo Therapeutics, Inc. Common Stock
$3.19HealthcareDelayed quote: Oct 6, 2026, 10:25 AM EDT
Total return — IKT vs LXEO
growth of $100 · dividends reinvested · last 3yIKT +94.2% (+24.8%/yr)LXEO -66.1% (-30.3%/yr)IKT compounded faster over this window
Log scale — wide-divergence pair
IKT LXEO
IKT vs LXEO: by the numbers
- •IKT is the larger company ($261M vs $250M market cap).
Metrics side by side
Valuation
| Metric | IKT | LXEO |
|---|---|---|
| P/B ratio | 1.71 | 1.06 |
Profitability
| Metric | IKT | LXEO |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -39.55% | -37.12% |
| ROIC | -42.92% | -39.76% |
Growth (annualized)
| Metric | IKT | LXEO |
|---|---|---|
| Total return CAGR (5Y) | -29.10% | N/A |
Go deeper
Dig into the metrics
Inhibikase Therapeutics ROELexeo Therapeutics, Inc. Common Stock ROEInhibikase Therapeutics operating marginLexeo Therapeutics, Inc. Common Stock operating marginInhibikase Therapeutics revenue growthLexeo Therapeutics, Inc. Common Stock revenue growthInhibikase Therapeutics free cash flowLexeo Therapeutics, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.